JPOST Repositoryapplication/xmlhttps://storage.jpostdb.org/JPST004154/files/CL-6_Con_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Cis_IC50_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Be_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Cis_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Be_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_At_IC50_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_At_IC50_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Con_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Be_IC50_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_At_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_At_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Cis_IC50_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Be_IC50_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Con_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Cis_IC50_48H_2.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_At_IC50_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Be_IC50_48H_1.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Be_IC50_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/H1_Cis_IC50_48H_3.mzXMLhttps://storage.jpostdb.org/JPST004154/files/CL-6_Cis_IC50_48H_3.mzXMLprimaryOK200ProteomicsWanna ChajaroenkulHomo Sapiens (human)https://repository.jpostdb.org/entry/JPST004154BIOTECjPOSTfalseIntegrative proteomic layers from extracellular vesicles (EVs) identify candidate biomarkers, candidate drug target and guide subtype-specific drug prioritization from cholangiocarcinoma cell lines Cholangiocarcinoma (CCA) is a heterogeneous malignancy with poor prognosis and limited therapeutic options. Extracellular vesicles (EVs) are promising sources of tumor derived proteins that may serve as noninvasive biomarkers and provide insights into therapeutic response mechanisms. Sat Feb 21 00:00:00 GMT 2026PXD0701909606